What's in Santen Inc.'s pipeline?

Santen Inc. has 19 drugs in our index: 4 marketed, 0 filed, 2 in Phase 3, 9 in Phase 2, 4 in Phase 1.

Which companies overlap with Santen Inc.'s portfolio?

Top competitors by shared drug class: Santen Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Santen Pharmaceutical Asia Pte. Ltd..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/santen-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

Santen Inc. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Santen Inc. pipeline: 4 marketed, 0 filed, 2 Phase 3, 9 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

4 marketed 0 filed 2 Phase 3 9 Phase 2 4 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Lucentis	Lucentis	marketed		Vascular endothelial growth factor A	Metabolic
0.0015% tafluprost	0.0015% tafluprost	marketed
1.5% levofloxacin ophthalmic solution	1.5% levofloxacin ophthalmic solution	marketed
0.005% Latanoprost Ophthalmic Solution	0.005% Latanoprost Ophthalmic Solution	marketed
DE-117	DE-117	phase 3	Rho kinase (ROCK) inhibitor	ROCK1/ROCK2	Ophthalmology
DE-117 Ophthalmic Solution	DE-117 Ophthalmic Solution	phase 3	Rho kinase (ROCK) inhibitor	ROCK1/ROCK2	Ophthalmology

Therapeutic area mix

Ophthalmology · 5
Metabolic · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Santen Pharmaceutical Co., Ltd. · 2 shared drug classes
Otsuka Pharmaceutical Co., Ltd. · 1 shared drug class
Santen Pharmaceutical Asia Pte. Ltd. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Santen Inc.:

Cite this brief

Drug Landscape (2026). Santen Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/santen-inc. Accessed 2026-06-10.